Biosimilar medicines: impact, opportunities and strategies. Twelve years of experience in Europe

Med Clin (Barc). 2019 May 17;152(10):411-415. doi: 10.1016/j.medcli.2018.11.013. Epub 2019 Jan 22.

[Article in English, Spanish]

Authors

Olga Delgado Sánchez¹, Daniel Ginard Vicens², Antonia Sampol Mayol³, Josefa Terrasa Pons⁴

Affiliations

¹ Servicio de Farmacia, Hospital Universitario Son Espases, Palma de Mallorca, España. Electronic address: olga.delgado@ssib.es.
² Servicio de Aparato Digestivo, Hospital Universitario Son Espases, Palma de Mallorca, España.
³ Servicio de Hematología, Hospital Universitario Son Espases, Palma de Mallorca, España.
⁴ Servicio de Oncología, Hospital Universitario Son Espases, Palma de Mallorca, España.

PMID: 30683321
DOI: 10.1016/j.medcli.2018.11.013

No abstract available

Publication types

Review

MeSH terms

Attitude
Biosimilar Pharmaceuticals* / economics
Biosimilar Pharmaceuticals* / supply & distribution
Biosimilar Pharmaceuticals* / therapeutic use
Cost Control
Drug Approval
Drug Costs / trends
Drug Utilization
European Union
Health Care Costs / trends
Humans
Marketing of Health Services
Patient Acceptance of Health Care
Retrospective Studies

Substances

Biosimilar Pharmaceuticals